Bone-targeted exosomes delivering betaine reverse bone loss in osteoporotic rats
The engineered delivery vehicle enhances autophagy in senescent stem cells and suppresses osteoclast activity to restore bone metabolic homeostasis.
Advanced materials (Deerfield Beach, Fla.) · Li X et al. · Paper published 27 Sep 2026
In ovariectomized rats, researchers tested an engineered nanodelivery system designed to deliver betaine directly to bone tissue. The platform, termed BZ@Exos, combines betaine-loaded metal-organic frameworks with exosomes engineered to co-overexpress CXCR4 for bone targeting and CD47 to avoid clearance by the mononuclear phagocyte system. Once internalized, betaine binds 14-3-3 proteins to trigger TFEB nuclear translocation. This process enhanced autophagic flux in senescent bone marrow mesenchymal stem cells and promoted their osteogenic differentiation. Concurrently, the treatment inhibited osteoclast-mediated bone resorption. When administered intravenously, the therapy reversed bone loss, improved bone microstructure, and alleviated senescence-related phenotypes in the osteoporotic rats.
Why it matters
Restoring autophagic flux in senescent stem cells addresses a primary cellular driver of impaired tissue regeneration during aging. Targeting this pathway while simultaneously curbing bone resorption highlights a dual-action approach for managing age-associated metabolic bone disorders.
Caveats
The study was conducted exclusively in cell cultures and ovariectomized rat models, so the findings cannot be directly applied to human osteoporosis without clinical validation.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Bone-Targeted Engineered Exosomes Delivering Betaine Alleviate Osteoporosis via Autophagy-Driven Osteogenesis
Li X, Li M, Li Z et al.
Advanced materials (Deerfield Beach, Fla.) · 27 Sep 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.